Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
Saru Basnet, João M. Santos, Dafne C.A. Quixabeira, James H.A. Clubb, Susanna Grönberg-Vähä-Koskela, Victor Arias, Santeri A. Pakola, Tatiana V. Kudling, Camilla Heiniö, Riikka Havunen, Víctor Cervera-Carrascón, Suvi Sorsa, Marjukka Anttila, Anna Kanerva, Akseli Hemminki
Abstract
, TILT-321 treatment led to effective antitumor efficacy mediated by increased intratumoral T cell activity in an A549 and patient-derived ovarian cancer xenograft mouse model humanized with peripheral blood mononuclear cells (PBMC). This study provides a proof of concept for an effective strategy to overcome the key limitations of recombinant bispecific T cell engager delivery for solid tumor treatment.
Topics & Concepts
Oncolytic virusCancer researchT cellImmunotherapyCancer immunotherapyPeripheral blood mononuclear cellIn vivoCellMedicineBiologyIn vitroImmunologyImmune systemTumor cellsBiotechnologyGeneticsBiochemistryCAR-T cell therapy researchVirus-based gene therapy researchMonoclonal and Polyclonal Antibodies Research